J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1292KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 91(9): 1360-1363, 1990

Report on the annual meeting

EVALUATION OF MULTIMODALITY THERAPY FOR THORACIC ESOPHAGEAL CANCER IN THE ANALYSIS OF PROGNOSIS

Second Department of Surgery, School of Medicine, Chiba University, Chiba, Japan

Kazuaki Okuyama, Shoichi Onoda, Teruo Kouzu, Noriyuki Tohnosu, Yoshio Koide, Tomotaka Awano, Kaichi Isono

Evaluation was made in multimodality therapy for 913 thoracic esophageal cancer patients operated on during 1959-1989. The a-factor dominant patients with a2 n(-)～1 in stage III and a3 n(-)～2 in stage IV were significantly favorable in survival between pre- and postoperative combined therapy group and no therapy group. However, no significant difference was seen in the n-factor dominant patients between the groups with and without combined therapy. The extended dissection (neck, mediasinum and abdomen) was significantly superior in survival to the conventional dissection (mediastinum and abdomen in the three groups with n1, 2, n2 and n3.
In conclusion, pre- and postoperative combined therapy will be significant in improving prognosis of the a-factor dominant patients with stages III+IV. But extended dissection and postoperative effective chemotherapy will be required in order to improve prognosis of the n-factor dominant advanced esophageal cancer patients.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.